BORTEZOMIB-RITUXIMAB RESULTS IN IMPROVED PFS AND RESPONSE RATES VERSUS RITUXIMAB, AND QUALITY OF RESPONSE IS ASSOCIATED WITH IMPROVED OUTCOMES, IN PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA (FL)

Konference: 2011 16th Congres of the European Hematology Association – účast ČR

Kategorie: Maligní lymfomy a leukémie

Téma: Non-Hodgkin lymphoma - Clinical 1

Číslo abstraktu: 0361

Autoři: MD Bertrand Coiffier; Evgenii Osmanov; Xiaonan Hong; Adriana Scheliga; prof. MUDr. Jiří Mayer, CSc.; MD Fritz C. Offner, PhD; prof. Simon A. Rule; Adriana Teixeira; MD Jan Andrzej Walewski, Ph.D.; MD Michael Crump, FRCPC; MD Ofer Shpilberg, MPH; Robert Hermann; MD Dixie-Lee Esseltine, FRCPC; Eugene Zhu; Christopher Enny; Panteli Theocharous; MD Helgi van de Velde, PhD; Yusri A Elsayed; Pier Luigi Zinzani

Datum přednesení příspěvku: 10. 6. 2011